Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » .11 and Up! » ACTC -- News Out !!! Sounds Like Government Funding

 - UBBFriend: Email this page to someone!    
Author Topic: ACTC -- News Out !!! Sounds Like Government Funding
Ace of Spades
Member


Rate Member
Icon 1 posted      Profile for Ace of Spades         Edit/Delete Post   Reply With Quote 
Chairman of Advanced Cell Technology's Ethics Advisory Board Testifies Before U.S. Senate Subcommittee

Wednesday, September 06, 2006 12:15 ET

WORCESTER, Mass., Sep 06, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (OTCBB:ACTC.OB) today announced that Ronald Green, Ph.D., Director of Dartmouth College's Ethics Institute and Chairman of the Advanced Cell Technology's Ethics Advisory Board testified today before the Senate Labor, Health & Human Services and Education Appropriations Subcommittee. Dr. Green's testimony focused on the benefits of In Vitro Fertilization and Preimplantation Genetic Diagnosis, and how the method developed by Advanced Cell Technology for generating human embryonic stem cells maintains the developmental potential of the embryo. Additionally, Dr. Green discussed the important roles of both Congress and the President in potentially allowing federal funding for stem cell lines derived using Advanced Cell Technology's method, which was published online (ahead of print) on August 23 in the peer-reviewed journal Nature.

While discussing Advanced Cell Technology's method for deriving human embryonic stem cells, Dr. Green explained, "I believe that the method of stem cell derivation announced by Advanced Cell Technology researchers in their August 24 report in the journal Nature represents a real opportunity to move human embryonic stem cell research forward in this country in a way that respects the ethical sensitivities of the vast majority of our citizens. The overwhelming majority of Americans support both IVF and PGD, as these procedures help infertile couples have children and allow those who carry genetic diseases to have healthy children."

In an effort to have Congress and the President consider funding stem cell lines generated through Advanced Cell Technology's method, Dr. Green stated, "If Congress were to approve legislation that funded research on lines generated by this new method, and if President Bush were to permit such legislation to pass into law, both the members of Congress and the President could honestly turn to the American people and say that no human embryo ever again needs to be harmed or destroyed to produce the stem cell lines we need for federally funded research."

Commenting on the embryos used in Advanced Cell Technology's research that were not allowed to develop, Dr. Green explained, "The embryos used were donated by people who had fully consented to the research and understood, and even required, that the embryos would not be allowed to go on to further development. It is not unique that the initial research needed to develop morally acceptable methods or materials do not meet everyone's approval, but this does not impugn the methods or materials produced as a result of that research."

About Advanced Cell Technology

Advanced Cell Technology, Inc. is a biotechnology company engaged in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit www.advancedcell.com.

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports including the quarterly report on Form 10-QSB for the period ending June 30, 2006.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE: Advanced Cell Technology, Inc.

Investors:
The Investor Relations Group
James Carbonara, 212-825-3210
or
Media:
Financial Dynamics
Jonathan Birt, 212-850-5634

Copyright Business Wire 2006


Public Companies Associated with this story:
(OTCBB: ACTC)

Posts: 2321 | Registered: Aug 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
BIGGG NEWS, POP!!!!!!!!!!

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
Ace of Spades
Member


Rate Member
Icon 1 posted      Profile for Ace of Spades         Edit/Delete Post   Reply With Quote 
This can break A Buck easy!

I expect huge News Coverage on this!

Posts: 2321 | Registered: Aug 2006  |  IP: Logged | Report this post to a Moderator
Schwabie
Member


Icon 4 posted      Profile for Schwabie     Send New Private Message       Edit/Delete Post   Reply With Quote 
LET'S SEE WHO WILL BE HOLDING THE BAG THIS TIME !

FROM $2.38 TO $0.66 IN 2 DAYS ! LMAO

FYI, THIS STOCK IS NOT BELOW 10 CENTS

--------------------
All I say is IMHO.

I like these calm little moments before the storm... Reminds me of Bethoven

Posts: 3255 | From: Orlando, FL | Registered: Mar 2006  |  IP: Logged | Report this post to a Moderator
Ace of Spades
Member


Rate Member
Icon 1 posted      Profile for Ace of Spades         Edit/Delete Post   Reply With Quote 
Green Calls for Stem Cell Support: $25 Million Would Go Toward Research
By Greg J. Borowski, Milwaukee Journal Sentinel

Sep. 6--Hartland -- Republican gubernatorial challenger Mark Green called Tuesday for spending $25 million over four years on research that seeks to replicate embryonic stem cells -- seen as the key to treating a long list of diseases -- without destroying the embryo.

Green's plan picks up on a recent announcement that scientists at a California biotech company were able to do just that. Researchers at Advanced Cell Technology established new stem cell lines after extracting single cells from embryos using a technique that is sometimes employed in genetic screening.

They destroyed the 16 embryos they started with, but many believe the technique could be a starting point to creating the lines while sparing the embryo.

Green said the technique proposed is promising and warrants state funding.

But his announcement was dismissed by aides to Democratic Gov. Jim Doyle who said the approach is unproven and an effort by Green to divert attention from his past votes in the U.S. House on stem cell research.

Doyle has repeatedly slammed Green on the issue, including running a TV ad that claimed Green wanted to outlaw stem cell research. The ad has been off the air for weeks, but Tuesday's announcement shows that stem cells remain a key issue in the race.

Voters will choose Nov. 7 among Green, Doyle and Green party candidate Nelson Eisman.

"We have an opportunity to look for answers," Green said, before criticizing Doyle as "trying to find a political sledgehammer" with the issue.

Green was joined Tuesday by a group of families of children with juvenile diabetes, echoing Doyle's approach of inviting reporters to meetings with such families around the state. State Sen. Ted Kanavas (R-Brookfield) also attended, voicing support for the new funding.

Doyle campaign spokesman Anson Kaye called Green's announcement a "red herring" aimed at hiding the fact "he opposes almost the entire waterfront of the research."

"Congressman Green's proposal would divert millions of dollars that could be used for proven stem cell research for something that hasn't been proven and may well be a false promise," Kaye said.

The $25 million, however, would be the first direct state funding used for embryonic stem cell research.

Under Doyle, $50 million in state funds is going toward building the $375 million Wisconsin Institutes for Discovery, where stem cell research will occur. Doyle has also told the Department of Commerce to use $5 million in incentives to attract stem cell companies to the state.

Green said the $25 million would be awarded to WiCell, a non-profit organization that is home to the federal government's National Stem Cell Bank. Researchers would have to do their work in the state.

Most research in the area is paid for by the federal government. That funding, though, faces limits imposed by President Bush and upheld by Congress, including through votes by Green, a four-term House member from Green Bay.

Federal funding may be used only for research on stem cell lines that existed in 2001, when Bush issued his order. Green said he would encourage Bush to make federal funding available for cells developed with the new technique.

Embryonic stem cells are considered vital to research because they can be coaxed to develop into any sort of specialized cell in the body.

Green and others, such as anti-abortion groups, have opposed federal funding for research that destroys embryos. Wisconsin Right to Life condemned the California study, since the embryos were ultimately destroyed.

Susan Armacost, chief lobbyist for the group, said her organization likes Green's proposal.

"We share a goal of wanting ethical, successful research," Armacost said. "It sounds like (Green) would like to take the research community in a new, more ethical direction."

On Tuesday, Green also urged Bush to allow federal funding for "any (stem cells) derived with this technique, derived in an ethical way, derived without destroying human embryos."

Matt Canter, spokesman for the governor's office, said that Green, unlike Doyle, would invest the $25 million "into a technique -- not cures" for diabetes and other crippling diseases.

John Rogers, chairman of the Doyle campaign's Stem Cell Champions for Doyle committee, said it was "irresponsible" to put the money toward the new area "while starving research that is proven."

Rogers, who is involved with the Parkinson Action Network, said scientists "have to tell us where they see the most progress and the most hope."

He said that the most immediate promise for cures and treatment is in using the techniques that Bush blocked with a veto. Green voted to uphold the veto.

"It's encouraging that candidate Green is talking about devoting state dollars to stem cell research in forms other than bricks and mortar," said Tom Still, president of the Wisconsin Technology Council.

"If you're a stem cell researcher in Wisconsin, perhaps this is a signal to you from candidate Green that there's some core recognition about the value of your work," Still said.

Kathleen Gallagher in Milwaukee and Steven Walters in Madison contributed to this report.

-----

Copyright (c) 2006, Milwaukee Journal Sentinel

Distributed by McClatchy-Tribune Business News.

For reprints, email tmsreprints*permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.
http://www.redorbit.com/news/health/646510/green_calls_for_stem_cell_support_25_ million_would_go/index.html?source=r_health
NASDAQ-OTCBB:ACTC,

Posts: 2321 | Registered: Aug 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
Its out of your price range schwabie.lmao

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
Schwabie
Member


Icon 4 posted      Profile for Schwabie     Send New Private Message       Edit/Delete Post   Reply With Quote 
THIS IS COMING FROM THE COMPANY THAT SAID THEY DID NOT DESTROY THE 16 EMBRYOS... IT WAS ALL OVER THE MEDIA

THE DAY AFTER ALL OVER THE NEWS ... ALL 16 EMBRYOS DESTROYED !

THEY NEED TO MAKE UP THEIR MINDS IMO !

--------------------
All I say is IMHO.

I like these calm little moments before the storm... Reminds me of Bethoven

Posts: 3255 | From: Orlando, FL | Registered: Mar 2006  |  IP: Logged | Report this post to a Moderator
Ace of Spades
Member


Rate Member
Icon 1 posted      Profile for Ace of Spades         Edit/Delete Post   Reply With Quote 
ACTC Huge 8K just out! avoids lawsuit,receives $$$$

On August 30, 2006, the Company entered into a License and Settlement Agreement between the Company, the University of Massachusetts (the “University”) and Start Licensing, Inc. (“Start”) relating to the settlement of the patent interference actions most recently described in Item 8 of the Company’s Quarterly Report on Form 10-QSB filed on August 11, 2006 (“Geron-Related Proceedings”). The terms of the License and Settlement Agreement include an initial payment to the Company of $500,000 and milestone payments to the Company of up to $750,000. In addition, Start, Geron Corporation and Roslin Institute (“Roslin”) each agreenot to suethe Company under certain patent applications owned by Roslin. In exchange, the Company and the University agreed to dismiss their appeal in the Geron-Related Proceedings with prejudice, transfer control of related University patents to Start and pay certain legal fees. Under the terms of the settlement agreement, the Company retained its rights under the University patents in the human field.

Posts: 2321 | Registered: Aug 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
$$$$$$$$$$$$$$$$$$$$$$$$$$$$4ME,LOL

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
Ace of Spades
Member


Rate Member
Icon 1 posted      Profile for Ace of Spades         Edit/Delete Post   Reply With Quote 
http://www.bizjournals.com/boston/stories/2006/09/04/daily13.html?from_rss=1

Advanced Cell Technology, Geron settle flap over cloning patents

Boston Business Journal - 10:59 AM EDT Wednesday

Advanced Cell Technology Inc. and Geron Corp. have settled a lawsuit over patents covering cloning technology. The dispute involved certain nuclear transfer cloning patents and patent applications.

In an agreement announced Wednesday, Advanced Cell and the University of Massachusetts will dismiss an appeal and transfer control of certain patents in the animal field, while retaining rights in the human field. Geron (Nasdaq: GERN) and its joint venture partner, Exeter Life Sciences, will retain all rights to the technology for use in human cells, Geron said in a separate statement.


The Geron joint venture also agreed to pay Advanced Cell $500,000 and milestone payments of as much as $750,000, Advanced Cell said in a statement.

"This settlement resolves the parties' various patent rights with respect to nuclear transfer cloning in the non-human field. The parties are now free to move forward with their respective business models unfettered by this patent dispute," William M. Caldwell, CEO of ACT, said in the statement.

Advanced Cell Technology is a biotechnology company with facilities in Worcester, Mass., and Alameda, Calif.

Posts: 2321 | Registered: Aug 2006  |  IP: Logged | Report this post to a Moderator
Schwabie
Member


Icon 1 posted      Profile for Schwabie     Send New Private Message       Edit/Delete Post   Reply With Quote 
Refiles to fix typo in headline

Sept 6 (Reuters) - Biotechnology company Geron Corp. (GERN.O: Quote, Profile, Research) on Wednesday said a U.S. district court dismissed appeals of two patent interference decisions relating to patents covering cloning technology.

Geron had acquired rights to the nuclear transfer technology from the Roslin Institute in 1999 and subsequently initiated patent interferences with conflicting patents held by the University of Massachusetts, the company said.

The U.S. Patent Office had ruled in favor of Geron on all counts in both interferences, and the university and its licensee, Advanced Cell Technology (ACTC.OB: Quote, Profile, Research), filed appeals. Both appeals have now been dismissed with prejudice by the university and ACT, the statement said. (Reporting by Ankur Relia in Bangalore)

--------------------
All I say is IMHO.

I like these calm little moments before the storm... Reminds me of Bethoven

Posts: 3255 | From: Orlando, FL | Registered: Mar 2006  |  IP: Logged | Report this post to a Moderator
stockonyou
Member


Member Rated:
4
Icon 1 posted      Profile for stockonyou     Send New Private Message       Edit/Delete Post   Reply With Quote 
I just sold my position, so do you?
Posts: 109 | From: Florida | Registered: Feb 2005  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
NO!

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
Schwabie
Member


Icon 1 posted      Profile for Schwabie     Send New Private Message       Edit/Delete Post   Reply With Quote 
quote:
Originally posted by stockonyou:
I just sold my position, so do you?

Good job. READ THE NEWS I POSTED.

Apparently no one is willing to give the whole story !

If you are going to post the news..

POST ALL OF THEM ! NOT JUST THE GOOD ONES !

THEY LOST !

--------------------
All I say is IMHO.

I like these calm little moments before the storm... Reminds me of Bethoven

Posts: 3255 | From: Orlando, FL | Registered: Mar 2006  |  IP: Logged | Report this post to a Moderator
Schwabie
Member


Icon 4 posted      Profile for Schwabie     Send New Private Message       Edit/Delete Post   Reply With Quote 
SLOWLY DOWN SHE GOES !

--------------------
All I say is IMHO.

I like these calm little moments before the storm... Reminds me of Bethoven

Posts: 3255 | From: Orlando, FL | Registered: Mar 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
Sep 6, 2006 12:17:38 PM

WORCESTER, Mass., Sep 06, 2006 (BUSINESS WIRE) --

Advanced Cell Technology, Inc. (OTCBB:ACTC) today announced that Robert Lanza, M.D., Advanced Cell Technology's Vice President of Medical and Stem Cell Development, testified today before the Senate Labor, Health & Human Services and Education Appropriations Subcommittee. Dr. Lanza's testimony focused on support for wider availability of human embryonic stem cells for basic medical research. Dr. Lanza is the principle author of a paper published online (ahead of print) on August 23 in the peer-reviewed journal Nature, which described a technique for developing human embryonic stem cells with a single-cell biopsy technique called Preimplantation Genetic Diagnosis (PGD). This technique is not harmful to embryos.

"Our hope is that the new method we described in Nature can be used to increase the number of cell lines that qualify for federal funding within the framework of existing U.S. laws and regulations," Dr. Lanza said.

William Caldwell, Advanced Cell Technology's Chief Executive Officer commented, "We believe our technology offers a significant forward step in the field of regenerative medicine and adds to the array of available technologies. Since Dr. Lanza testified here last year, we have progressed from applying the single-cell derivation technique from the mouse to the human. In that year alone, a million people died from diseases that could that could potentially be treated--and possibly cured--using future stem cell therapies. We urge wider availability of cell lines for medical research."

About Advanced Cell Technology

Advanced Cell Technology, Inc. is a biotechnology company engaged in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit www.advancedcell.com.

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports including the quarterly report on Form 10-QSB for the period ending June 30, 2006.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE: Advanced Cell Technology, Inc.

For Advanced Cell Technology, Inc. Investors: The Investor Relations Group James Carbonara, 212-825-3210 or Media: Financial Dynamics Jonathan Birt, 212-850-5634

Copyright Business Wire 2006

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
Business Wire via COMTEX


Sep 6, 2006 12:15:25 PM

Testimony Urges Legislative and Executive Branches of the U.S. Federal
Government to Consider Funding Stem Cell Lines Generated by Company's
Technique that Maintains Developmental Potential of Embryo

WORCESTER, Mass., Sep 06, 2006 (BUSINESS WIRE) --

Advanced Cell Technology, Inc. (OTCBB:ACTC.OB) today announced that Ronald Green, Ph.D., Director of Dartmouth College's Ethics Institute and Chairman of the Advanced Cell Technology's Ethics Advisory Board testified today before the Senate Labor, Health & Human Services and Education Appropriations Subcommittee. Dr. Green's testimony focused on the benefits of In Vitro Fertilization and Preimplantation Genetic Diagnosis, and how the method developed by Advanced Cell Technology for generating human embryonic stem cells maintains the developmental potential of the embryo. Additionally, Dr. Green discussed the important roles of both Congress and the President in potentially allowing federal funding for stem cell lines derived using Advanced Cell Technology's method, which was published online (ahead of print) on August 23 in the peer-reviewed journal Nature.

While discussing Advanced Cell Technology's method for deriving human embryonic stem cells, Dr. Green explained, "I believe that the method of stem cell derivation announced by Advanced Cell Technology researchers in their August 24 report in the journal Nature represents a real opportunity to move human embryonic stem cell research forward in this country in a way that respects the ethical sensitivities of the vast majority of our citizens. The overwhelming majority of Americans support both IVF and PGD, as these procedures help infertile couples have children and allow those who carry genetic diseases to have healthy children."

In an effort to have Congress and the President consider funding stem cell lines generated through Advanced Cell Technology's method, Dr. Green stated, "If Congress were to approve legislation that funded research on lines generated by this new method, and if President Bush were to permit such legislation to pass into law, both the members of Congress and the President could honestly turn to the American people and say that no human embryo ever again needs to be harmed or destroyed to produce the stem cell lines we need for federally funded research."

Commenting on the embryos used in Advanced Cell Technology's research that were not allowed to develop, Dr. Green explained, "The embryos used were donated by people who had fully consented to the research and understood, and even required, that the embryos would not be allowed to go on to further development. It is not unique that the initial research needed to develop morally acceptable methods or materials do not meet everyone's approval, but this does not impugn the methods or materials produced as a result of that research."

About Advanced Cell Technology

Advanced Cell Technology, Inc. is a biotechnology company engaged in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit www.advancedcell.com.

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports including the quarterly report on Form 10-QSB for the period ending June 30, 2006.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE: Advanced Cell Technology, Inc.

Investors: The Investor Relations Group James Carbonara, 212-825-3210 or Media: Financial Dynamics Jonathan Birt, 212-850-5634

Copyright Business Wire 2006

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
Business Wire via COMTEX


Sep 6, 2006 8:00:57 AM

ALAMEDA, Calif., Sep 06, 2006 (BUSINESS WIRE) --

Advanced Cell Technology, Inc. (OTCBB: ACTC) (ACT) announced today that it has settled a patent dispute involving certain nuclear transfer cloning patents and patent applications owned or licensed by the University of Massachusetts (UMass), Roslin Institute (Roslin), Geron Corporation (Nasdaq: GERN) (Geron), Start Licensing, Inc. (Start) and ACT. The dispute involved appeals to the U.S. District Court by ACT and UMass that sought to overturn rulings by the U.S. Patent and Trademark Office against ACT and UMass in patent interference numbers 104,746 and 105,192.

The underlying interference proceedings centered around patent applications owned by Roslin against U.S. Patents 5,945,577 and 6,234,970 owned by UMass and exclusively licensed to ACT. The interference proceedings were initiated by Roslin's licensee, Geron. In late 2004 and again in early 2005, the Board of Patent Appeals and Interferences of the U.S. Patent Office ruled in favor of Geron in both interferences. UMass and its licensee, ACT, immediately filed appeals, naming Roslin, Geron and Exeter Life Sciences (Exeter), also a Roslin licensee, as defendants. In mid-2005, Geron and Exeter established a joint venture company, Start Licensing, to manage and license intellectual property rights for animal reproductive technologies, and exclusively licensed their rights in Roslin patent applications to Start in the non-human animal field.

Under the terms of the settlement agreement, Start agreed to pay ACT an initial payment of $500,000 and milestone payments of up to $750,000. Start, Geron, Exeter and Roslin each further agreed not to sue ACT or UMass under the involved Roslin patent applications. In exchange, ACT and UMass dismissed their appeals with prejudice, transferred control of related UMass patents and patent applications to Start in the non-human animal field, and ACT paid certain legal fees. Under the terms of the settlement agreement, ACT retained its rights under the UMass patents in the human field.

"This settlement resolves the parties' various patent rights with respect to nuclear transfer cloning in the non-human field. The parties are now free to move forward with their respective business models unfettered by this patent dispute," said William M. Caldwell, CEO of ACT.

About Advanced Cell Technology

Advanced Cell Technology, Inc. is a biotechnology company engaged in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit www.advancedcell.com.

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports including the quarterly report on Form 10-QSB for the period ending June 30, 2006.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE: Advanced Cell Technology, Inc.

The Investor Relations Group Investor Relations: James Carbonara Media Relations: Bill Douglass 212-825-3210

Copyright Business Wire 2006

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
Ace of Spades
Member


Rate Member
Icon 1 posted      Profile for Ace of Spades         Edit/Delete Post   Reply With Quote 
 -


WASHINGTON (Reuters) - Senators trying to promote human stem cell research rebuked a team of corporate scientists on Wednesday, saying their claims to have produced human embryonic stem cells without harming the embryo had misrepresented their work and hurt the cause.

Last month, the team at Advanced Cell Technology in Massachusetts said they had taken single cells from days-old embryos and used them to produce batches, or lines, of stem cells.

They said their research, published in the prestigious science journal Nature, provided an ethical way to produce the controversial cells.

But Sen. Arlen Specter (news, bio, voting record), a Pennsylvania Republican who supports embryonic stem cell research, scolded the researchers, saying they had done no such thing.

"You made our job a lot tougher," said Specter, who has been trying to pass legislation that would expand federal funding of such experiments. President George W. Bush vetoed one bill in July.

At issue is whether the Advanced Cell team, led by Dr. Robert Lanza, actually did what they said they did because they conducted a laboratory experiment meant only to show the principle.

Such cells from embryos are considered enormously powerful, because they can produce any type of cell or tissue in the human body and might one day be used to regenerate body parts to treat diabetes, cancer or other conditions.

But opponents say it is unethical to experiment on human embryos, although it remains legal using private funds. Scientists complain that without federal funding and oversight, the field will languish in the United States even as it moves ahead in countries such as Britain.

LABORATORY EXPERIMENT

Lanza's team said they duplicated a method called preimplantation genetic diagnosis or PGD, in which one cell is taken from an hours-old embryo that consists of only eight to 10 cells.

In PGD, the cell is analyzed for severe genetic defects and if the embryo is found to be normal, it is implanted into the mother's womb using standard in vitro fertilization techniques. Some couples who know they carry the genes for fatal diseases use the method to conceive healthy children.

Experts say more than 1,500 such procedures have resulted in apparently normal births in the United States.

Removing one cell does not prevent the embryo from developing and Lanza's team said that cell could be used to generate embryonic stem cells.

But because it was a laboratory experiment, none of the embryos was implanted and in fact several were destroyed. And no cell lines were created from single cells, but instead created by incubating several cells together.

Opponents have used these facts to discredit the report.

"What they have done in this experiment is definitely not an ethical alternative," said Richard Doerflinger, who follows such issues for the U.S. Conference of Catholic Bishops.

"Whether a procedure like this could ever be turned into an ethical alternative is extremely unlikely in my view," Doerflinger said in a telephone interview.

Specter said the study's claims to provide an ethical alternative to destroying embryos "dramatic albeit false."

"This technique has been used throughout the world for years and years," retorted Lanza. "Everything I said is absolutely correct and accurate."

Later he told reporters he was confused by the questioning he received from Specter at the hearing of the Senate Labor, Health and Human Services subcommittee. "It is not fair. It is not right," Lanza said. "I know for a fact that removing the cell does not impact the embryo."

But Specter said the company had interfered with efforts to get a bill passed that would expand federal funding of the research. "We have to start again with a whole new bill and we will do it," he told reporters, adding that there were not yet enough votes to override Bush's veto.

 -

Posts: 2321 | Registered: Aug 2006  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share